Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amphastar Pharmaceuticals Receives FDA Approval for Semi-Purified Heparin at Amphastar Nanjing Pharmaceuticals
RANCHO CUCAMONGA, Calif. , June 04, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) supplement for the manufacture of semi-purified heparin
View HTML
Toggle Summary Amphastar Pharmaceuticals Receives FDA Approval for Calcium Chloride Injection
RANCHO CUCAMONGA, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) for Calcium Chloride injection 10% in the 10 mL Luer-Jet
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
RANCHO CUCAMONGA, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell , President, and Bill Peters , CFO, will be presenting at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 15, 2018 at 1:00 p.m.
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018
Reports Net Revenues of $58.4 Million for the Three Months Ended March 31, 2018 RANCHO CUCAMONGA, Calif. , May 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2018 .
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2018
RANCHO CUCAMONGA, Calif. , May 03, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2018 ended March 31, 2018 , after the market closes on Wednesday, May 9, 2018 , and will hold a conference call to
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Needham’s 17th Annual Healthcare Conference
RANCHO CUCAMONGA, Calif. , March 26, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters , CFO will be presenting at the Needham‘s 17 th Annual Healthcare Conference on Wednesday, March 28, 2018 at 9:30 a.m. Eastern Time in New York, NY .
View HTML
Toggle Summary Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc.
RANCHO CUCAMONGA, Calif. , March 21, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that on March 20, 2018 , the United States Court for the District of Massachusetts (the “District Court”) entered final judgment in favor of Amphastar in a lawsuit brought by
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2017
Reports Net Revenues of $60.4 Million for the Three Months Ended December 31, 2017 RANCHO CUCAMONGA, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months and fiscal year ended December
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12, 2018
RANCHO CUCAMONGA, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2017 ended December 31, 2017 , after the market closes on Monday, March 12, 2018 , and will hold a conference call to
View HTML
Toggle Summary Amphastar Announces Approval for Sodium Nitroprusside Injection, USP
RANCHO CUCAMONGA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that today the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application ("ANDA") for Sodium Nitroprusside Injection 25mg/mL, 2mL single
View HTML

 

Copyright ©2018 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States